Impact of the CYP3A4*1G Polymorphism and its Combination with CYP3A5 Genotypes on Tacrolimus Pharmacokinetics in Renal Transplant Patients

• Venkataramanan R , SwaminathanA, PrasadT et al.: Clinical pharmacokinetics of tacrolimus.Clin. Pharmacokinet.29(6) , 404–430 (1995).
   PubMed Web of Science ®Google Scholar
• Staatz CE , TettSE: Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation.Clin. Pharmacokinet.43(10) , 623–653 (2004).
   PubMed Web of Science ®Google Scholar
• Haufroid V , WallemacqP, van Kerckhove V et al.: CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: guidelines from an experimental study. Am. J. Transplant.6(11) , 2706–2713 (2006).
   PubMed Web of Science ®Google Scholar
• Hesselink DA , van Schaik RH, van der Heiden IP et al.: Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin. Pharmacol. Ther.74(3) , 245–254 (2003).
   PubMed Web of Science ®Google Scholar
• Tsuchiya N , SatohS, TadaH et al.: Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients.Transplantation78(8) , 1182–1187 (2004).
   PubMed Web of Science ®Google Scholar
• Roy JN , BaramaA, PoirierC, VinetB, RogerM: CYP3A4, CYP3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients.Pharmacogenet. Genomics16(9) , 659–665 (2006).
   PubMed Web of Science ®Google Scholar
• Tada H , TsuchiyaN, SatohS et al.: Impact of CYP3A5 and MDR1 (ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients.Transplant. Proc.37(4) , 1730–1732 (2005).
   PubMed Web of Science ®Google Scholar
• Haufroid V , MouradM, van Kerckhove V, et al.: The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics14(3) , 147–154 (2004).
   PubMedGoogle Scholar
• Satoh S , KagayaH, SaitoS et al.: Lack of tacrolimus circadian pharmacokinetics and CYP3A5 pharmacogenetics in the early and maintenance stages in Japanese renal transplant recipients.Br. J. Clin. Pharmacol.66(2) , 207–214 (2008).
   PubMed Web of Science ®Google Scholar
• Lin YS , DowlingAL, QuigleySD et al.: Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism.Mol. Pharmacol.62(1) , 162–172 (2002).
   PubMed Web of Science ®Google Scholar
• Lamba JK , LinYS, SchuetzEG, ThummelKE: Genetic contribution to variable human CYP3A-mediated metabolism.Adv. Drug. Deliv. Rev.54(10) , 1271–1294 (2002).
   PubMed Web of Science ®Google Scholar
• Satoh S , SaitoM, InoueT et al.: CYP3A5*1 allele associated with tacrolimus trough concentrations but not subclinical acute rejection or chronic allograft nephropathy in Japanese renal transplant recipients.Eur. J. Clin. Pharmacol.65(5) , 473–481 (2009).
   PubMed Web of Science ®Google Scholar
• Fukushima-Uesaka H , SaitoY, WatanabeH et al.: Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population.Hum. Mutat.23(1) , 100–108 (2004).
   PubMedGoogle Scholar
• Gao Y , ZhangLR, FuQ: CYP3A4*1G polymorphism is associated with lipid-lowering efficacy of atorvastatin but not of simvastatin.Eur. J. Clin. Pharmacol.64(9) , 877–882 (2008).
   PubMed Web of Science ®Google Scholar
• Du J , ZhangA, WangL et al.: Relationship between response to risperidone, plasma concentrations of risperidone and CYP3A4 polymorphisms in schizophrenia patients.J. Psychopharmacol.24(7) , 1115–1120 (2010).
   PubMed Web of Science ®Google Scholar
• Zhang W , ChangYZ, KanQC et al.: CYP3A4*1G genetic polymorphism influences CYP3A activity and response to fentanyl in Chinese gynecologic patients.Eur. J. Clin. Pharmacol.66(1) , 61–66 (2010).
   PubMed Web of Science ®Google Scholar
• Fukuen S , FukudaT, MauneH et al.: Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and *6, in a Japanese population.Pharmacogenetics12(4) , 331–334 (2002).
   PubMedGoogle Scholar
• Obayashi K , NakamuraK, KawanaJ et al.: VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients.Clin. Pharmacol. Ther.80(2) , 169–178 (2006).
   PubMed Web of Science ®Google Scholar
• Shiran MR , LennardMS, IqbalMZ et al.: Contribution of the activities of CYP3A4, CYP2D6, CYP1A2 and other potential covariates to the disposition of methadone in patients undergoing methadone maintenance treatment.Br. J. Clin. Pharmacol.67(1) , 29–37 (2009).
   PubMed Web of Science ®Google Scholar
• Kitamura Y , MoriguchiM, KanekoH et al.: Determination of probability distribution of diplotype configuration (diplotype distribution) for each subject from genotypic data using the EM algorithm.Ann. Hum. Genet.66(Pt 3) , 183–193 (2002).
   PubMed Web of Science ®Google Scholar
• MacPhee IA , FredericksS, TaiT et al.: The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation.Am. J. Transplant.4(6) , 914–919 (2004).
   PubMed Web of Science ®Google Scholar
• Spurr NK , GoughAC, StevensonK, WolfCR: The human cytochrome P450 CYP3A locus: assignment to chromosome 7q22-qter.Hum. Genet.81(2) , 171–174 (1989).
   PubMed Web of Science ®Google Scholar
• Finta C , ZaphiropoulosPG: The human cytochrome P450 3A locus. Gene evolution by capture of downstream exons.Gene260(1–2) , 13–23 (2000).
   PubMed Web of Science ®Google Scholar
• Domanski TL , HalpertJR: Analysis of mammalian cytochrome P450 structure and function by site-directed mutagenesis.Curr. Drug Metab.2(2) , 117–137 (2001).
   PubMed Web of Science ®Google Scholar
• Kuehl P , ZhangJ, LinY et al.: Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression.Nat. Genet.27(4) , 383–391 (2001).
   PubMed Web of Science ®Google Scholar
• Stevens JC : New perspectives on the impact of cytochrome P450 3A expression for pediatric pharmacology.Drug Discov. Today11(9–10) , 440–445 (2006).
   PubMed Web of Science ®Google Scholar
• Kuypers DR , de Jonge H, Naessens M, Lerut E, Verbeke K, Vanrenterghem Y: CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients. Clin. Pharmacol. Ther.82(6) , 711–725 (2007).
   PubMed Web of Science ®Google Scholar
• Miura Y , SatohS, SaitoM, et al.: Factors increasing quantitative interstitial fibrosis from 0-hour to 1-year in living kidney transplant patients receiving tacrolimus. Transplantation91(1) , 78–85 (2011).
   PubMed Web of Science ®Google Scholar

▪ Website

• The Human CYP Allele Nomenclature Committee‘s homepage www.imm.ki.se/cypalleles
   Google Scholar